Printer Friendly

Antidepressant Effect Seen for Anti-Inflammatories in MDD; Review shows reduced depressive symptoms for anti-inflammatory agents compared with placebo in MDD.

TUESDAY, Oct. 29, 2019 (HealthDay News) -- Anti-inflammatory agents seem to have an antidepressant effect for patients with major depressive disorder (MDD), according to a review published online Oct. 28 in the Journal of Neurology, Neurosurgery & Psychiatry.

Shuang Bai, from Tongji Hospital in Wuhan, China, and colleagues conducted a systematic review of the literature to examine the efficacy and safety of anti-inflammatory agents for MDD. Potentially relevant randomized controlled trials (RCTs) were identified up to Jan. 1, 2019; the quantitative analysis included 30 RCTs with 1,610 participants.

The researchers found that in an overall analysis pooling data from 26 of the RCTs, anti-inflammatory agents reduced depressive symptoms compared with placebo (standard mean difference, −0.55). Compared with those receiving placebo, patients receiving anti-inflammatory agents had higher response and remission rates (risk ratios, 1.52 and 1.79, respectively). Both the monotherapy and adjunctive treatment groups had a greater reduction in symptom severity in a subgroup analysis. Significant antidepressant effects for MDD were seen in a subgroup analysis of nonsteroidal anti-inflammatory drugs, omega-3 fatty acids, statins, and minocyclines. No difference in changes in depression severity was seen between the groups in women-only trials. There was also no difference noted between the groups in changes in quality of life.

"Anti-inflammatory agents show promising effects for MDD," the authors write. "However, owing to the chronic course of MDD, quality of life and adverse effects should be further investigated in high-quality randomized clinical trials with long-term follow-up."

Abstract/Full Text

COPYRIGHT 2019 HealthDay
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Physician's Briefings
Date:Oct 29, 2019
Words:247
Previous Article:Evidence for Use of Cannabinoids to Treat Mental Disorders Lacking; Evidence inadequate for cannabinoid use to relieve depression, anxiety, ADHD,...
Next Article:Racial Inequity Seen for Admission to Cardiology for Heart Failure; Black and Latinx patients have lower rates of admission to cardiology service, as...
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters